March 16th 2023
Kidney Cancer Association president Gretchen Vaughan discusses improvements being rolled out by the organization and the importance of multidisciplinary care.
Expert Perspectives on Emerging CDK4/6 Inhibitor Strategies in Advanced Prostate Cancer Management Settings
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Oncology Town Hall™: Primary Investigators Present Key Abstracts in Genitourinary Malignancies from Paris
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
Show Me Your Care Plan! Developing Multidisciplinary Strategies to Optimize the First-Line Care of Patients with mRCC
Medical Crossfire®: Key Questions on Sequencing, Radioligands, and Novel Emerging Approaches in CRPC
How Guidelines and Recent Clinical Trial Data Inform the Modern-Day Treatment of Advanced Prostate Cancer
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Cases and Conversations™: How The Experts Make Evidence-Based Treatment Decisions in Castration-Resistant Prostate Cancer
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Dose Reductions With Cabozantinib Associated With Improved Efficacy OutcomesFebruary 20th 2022
A surrogate for toxicity and drug exposure, cabozantinib dose reductions were tied to longer durations of time to treatment failure and overall survival for patients with metastatic renal cell carcinoma.
Type of Frontline Immunotherapy Does Not Affect Responses With Second-Line Cabozantinib in Advanced RCCFebruary 20th 2022
Treatment with cabozantinib in the second line yielded responses in patients with advanced renal cell carcinoma who received immunotherapy in the frontline, regardless of prior regimen.
Response Acheivement With Nivolumab Plus Ipilimumab Combo for Clear Cell RCC Linked With Immune Cell–Related FactirsFebruary 19th 2022
Data from the TITAN-RCC trial presented at 2022 ASCO GU showed that certain immune cell–related parameters may be predictive of response to nivolumab/ipilimumab in advanced or metastatic clear cell renal cell carcinoma
Chung-Han Lee, MD, PhD, Discusses Biomarkers for Response in RCC With Pembrolizumab Plus LenvatinibFebruary 19th 2022
Chung-Han Lee, MD, PhD, spoke about using biomarkers to help predict responses in patients with metastatic renal cell carcinoma treated on the KEYNOTE-146 study.
Expert Commentary on the product profile of Belzutifan for Renal Cell CarcinomaJanuary 18th 2022
In an interview with ONCOLOGY®, Natasha Khrystolubova, BPharm, RPh, BCOP, offers a comprehensive review of real-world treatment considerations of belzutifan as therapy for patients with renal cell carcinoma.
Belzutifan for RCC and non-RCC Neoplasms Associated With von Hippel-Lindau Disease Shows Encouraging Clinical ActivityDecember 5th 2021
The phase 2 MK-6482-004 trial found that belzutifan produced positive response data for patients with renal cell carcinoma and non–renal cell carcinoma neoplasms associated with von Hippel-Lindau disease.
Use of First-Line Post-Protocol Immunotherapy Appears Low in Kidney Cell Carcinoma Clinical TrialsNovember 22nd 2021
In a systemic review assessing the use of first-line post-protocol immunotherapy for patients with kidney cell carcinoma, investigators reported that use was low in randomized clinical trials among patients in the control group.
Adjuvant Pembrolizumab Approved by FDA for Treatment of Renal Cell Carcinoma in Certain CasesNovember 18th 2021
Patients with intermediate-risk and high-risk renal cell carcinoma had a statistically significant improvement in disease-free survival after being treated with pembrolizumab, which was approved by the FDA.
John Burke, MD, Discuses the Key Findings of the KEYNOTE-564 Trial With Pembrolizumab in High-Risk RCCNovember 17th 2021
CancerNetwork®sat down with John Burke, MD, to talk about the topline results in the KEYNOTE-564 trial, which examined the use of pembrolizumab in a population of patients with high-risk renal cell carcinoma.